Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 179, Issue 1, Pages 54-62
Publisher
Wiley
Online
2017-09-26
DOI
10.1111/bjd.16004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
- (2016) Robert Bissonnette et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
- (2015) Florence J. Dalgard et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis
- (2014) Lindsey A. MacFarlane et al. International Journal of Rheumatic Diseases
- Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo
- (2014) Helen L. Wright et al. RHEUMATOLOGY
- JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
- (2014) Leeyen Hsu et al. Journal of Immunology Research
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Jakpot! New small molecules in autoimmune and inflammatory diseases
- (2013) Kamran Ghoreschi et al. EXPERIMENTAL DERMATOLOGY
- Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies
- (2013) P.L. Mattei et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
- (2012) Apostolos Kontzias et al. CURRENT OPINION IN PHARMACOLOGY
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- On Efficiency of Constrained Longitudinal Data Analysis Versus Longitudinal Analysis of Covariance
- (2009) Kaifeng Lu BIOMETRICS
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started